BMS Group Ltd

Industry:

Insurance

Description

The first company in the BMS Group (Ballantyne, McKean & Sullivan Ltd) was founded in 1980 and admitted as a Lloyd's broker in 1984. BMS initially focused on placing North American non-marine reinsurance business in the London and European markets, but rapidly grew and expanded its range of specialist insurance and reinsurance services. As a result of this the Group now comprises a dozen operating companies serving clients in the UK, Continental Europe, North America and many other parts of the world. Through a unique "corporate partnership" structure, BMS Group member companies can focus on providing innovative solutions to their clients' needs, while benefiting from the collective strength of the Group in terms of market presence, back office administration and the application of information technology.

View More Statistics

Site Statistics

Monthly Unique Visitors:	1,027
Site Rank:	1,116,956
Trust Rating:	Neutral
Stats by

News Archive

Research from M. Ogita and co-researchers yields new findings on heart disease. Heart Disease Weekly; 7/26/2009 ...the SES group versus 9.4% in the BMS group (P = 0.04). At 3-year clinical...group compared with 15.9% in the BMS group (P = 0.18). Only one case of...stent thrombosis occurred in the BMS group (late and very late thrombosis... ...more

VIVA 2009 Late-Breaking Trials Highlight Advances in Interventional Treatments of Peripheral Arterial Disease.(Clinical report) Heart Disease Weekly; 11/29/2009 ...there were 69 limbs in the V12 group and 63 limbs in the BMS group. The results showed that 95.4% of patients in the...restenosis (Duplex scan) compared to 82.2% in the BMS group (P < .05). The investigators found that there was... ...more

New cardiology study findings have been reported by D.T. Ko and co-researchers. Cardiovascular Week; 11/23/2009 ...observed among 6.9% in the DES group and 7.1% in the BMS group that did not fill a single prescription of thienopyridine...progressive manner, with 28% in the DES group and 34% in the BMS group discontinuing therapy by 6 months. Low-income patients... ...more